Solas C - Search Results

1

A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma.

Ferrer F, Solas C, Giocanti M, Lacarelle B, Deville JL, Gravis G, Ciccolini J. Ferrer F, et al. Among authors: solas c. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Feb 1;1138:121968. doi: 10.1016/j.jchromb.2020.121968. Epub 2020 Jan 7. J Chromatogr B Analyt Technol Biomed Life Sci. 2020. PMID: 31931326

2

Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.

Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Loko MA, et al. Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419. Epub 2012 Oct 10. Antivir Ther. 2012. PMID: 23052829

3

Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection.

Dumon C, Solas C, Thuret I, Chambost H, Lacarelle B, Michel G, Durand A. Dumon C, et al. Among authors: solas c. Ther Drug Monit. 2000 Aug;22(4):402-8. doi: 10.1097/00007691-200008000-00007. Ther Drug Monit. 2000. PMID: 10942179

4

'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study.

Duran S, Solas C, Spire B, Carrieri MP, Fuzibet JG, Costagliola D, Lacarelle B, Moatti JP; Cohort Manif 2000 Study Group. Duran S, et al. Among authors: solas c. AIDS. 2001 May 25;15(8):1075-7. doi: 10.1097/00002030-200105250-00024. AIDS. 2001. PMID: 11399998 Clinical Trial. No abstract available.

5

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Lafeuillade A, et al. Among authors: solas c. HIV Clin Trials. 2002 Jan-Feb;3(1):27-35. doi: 10.1310/WMWL-6W9Y-PXV2-X148. HIV Clin Trials. 2002. PMID: 11819183

6

High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen.

Solas C, Basso S, Poizot-Martin I, Ravaux I, Gallais H, Gastaut JA, Durand A, Lacarelle B. Solas C, et al. J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):374-7. doi: 10.1097/00126334-200204010-00008. J Acquir Immune Defic Syndr. 2002. PMID: 11917242

7

Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data.

Solas C, Petit N, Orticoni M, Durand A, Gastaut JA, Lacarelle B. Solas C, et al. Pathol Biol (Paris). 2002 Nov;50(9):565-7. doi: 10.1016/s0369-8114(02)00342-5. Pathol Biol (Paris). 2002. PMID: 12490421

8

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.

Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Solas C, et al. Antimicrob Agents Chemother. 2003 Jan;47(1):238-43. doi: 10.1128/AAC.47.1.238-243.2003. Antimicrob Agents Chemother. 2003. PMID: 12499197 Free PMC article. Clinical Trial.

9

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.

Solas C, Poizot-Martin I, Drogoul MP, Ravaux I, Dhiver C, Lafeuillade A, Allegre T, Mokhtari M, Moreau J, Lepeu G, Petit N, Durand A, Lacarelle B. Solas C, et al. Br J Clin Pharmacol. 2004 Apr;57(4):436-40. doi: 10.1046/j.1365-2125.2003.02020.x. Br J Clin Pharmacol. 2004. PMID: 15025741 Free PMC article.

10

Seventy-two-hour stability of Taxol in 5% dextrose or 0.9% sodium chloride in Viaflo, Freeflex, Ecoflac and Macoflex N non-PVC bags.

Pourroy B, Botta C, Solas C, Lacarelle B, Braguer D. Pourroy B, et al. Among authors: solas c. J Clin Pharm Ther. 2005 Oct;30(5):455-8. doi: 10.1111/j.1365-2710.2005.00669.x. J Clin Pharm Ther. 2005. PMID: 16164492

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters